Clinical Evidence: STEP & SELECT Trial Programs
Wegovy is backed by the largest randomized clinical trial program in the history of obesity medicine. In the landmark STEP 1 trial (Wilding et al., New England Journal of Medicine 2021; 384:989-1002, DOI: 10.1056/NEJMoa2032183), 1,961 adults with a BMI $\ge 30$ (or $\ge 27$ with comorbidity) were randomized 2:1 to once-weekly semaglutide 2.4 mg or placebo alongside lifestyle interventions over 68 weeks.
| Trial & Endpoint | Cohort ($n$) | Semaglutide 2.4mg | Placebo | Treatment Difference |
|---|---|---|---|---|
| STEP 1 (Mean Weight Loss) | 1,961 | -14.9% (-15.3 kg) | -2.4% (-2.6 kg) | -12.4% (95% CI -13.4 to -11.5), p < 0.001 |
| STEP 1 (>=5% Weight Loss) | 1,961 | 86.4% of patients | 31.5% of patients | +54.9 percentage points, p < 0.001 |
| STEP 1 (>=10% Weight Loss) | 1,961 | 69.1% of patients | 12.0% of patients | +57.1 percentage points, p < 0.001 |
| STEP 1 (>=15% Weight Loss) | 1,961 | 50.5% of patients | 4.9% of patients | +45.6 percentage points, p < 0.001 |
| STEP 1 (>=20% Weight Loss) | 1,961 | 32.0% of patients | 1.7% of patients | +30.3 percentage points, p < 0.001 |
| SELECT (3-Point MACE) | 17,604 | 6.5% event rate | 8.0% event rate | HR 0.80 (95% CI 0.72–0.90), p < 0.001 |
| STEP 5 (2-Year Sustainability) | 304 | -15.2% sustained loss | -2.6% sustained loss | -12.6% difference maintained at 104 weeks |
Wegovy 5-Step Dosage & Titration Protocol
Wegovy is packaged in color-coded, single-dose pre-filled pens. Each pen delivers a preset dose with a hidden needle that deploys automatically upon pressing against the skin. Patients escalate through five discrete dose tiers at 4-week intervals:
| Escalation Tier | Duration | Weekly Dose | Pen Color | Clinical Objective |
|---|---|---|---|---|
| Month 1 (Initiation) | Weeks 1–4 | 0.25 mg weekly | Teal Pen | Receptor priming & initial GI accommodation |
| Month 2 (Escalation 1) | Weeks 5–8 | 0.5 mg weekly | Red Pen | Beginning metabolic satiety signaling |
| Month 3 (Escalation 2) | Weeks 9–12 | 1.0 mg weekly | Brown Pen | Significant appetite reduction & glycemic stabilization |
| Month 4 (Escalation 3) | Weeks 13–16 | 1.7 mg weekly | Blue Pen | Accelerated fat mass oxidation phase |
| Month 5+ (Maintenance) | Week 17 onward | 2.4 mg weekly | Black Pen | Full clinical therapeutic dose for chronic maintenance |
Get Started with Authentic Wegovy
Flat $899/mo rate across all doses. Save up to $100 on your first month order. Free 2-day cold-chain shipping and board-certified medical management.
See If You QualifyClinical Safety Profile & Black Box Warning
Wegovy carries an FDA Boxed Warning for Risk of Thyroid C-Cell Tumors. In rodent carcinogenicity studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.
BOXED WARNING & STRICT CONTRAINDICATIONS
- Contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC).
- Contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Contraindicated in patients with known severe hypersensitivity to semaglutide.
- Contraindicated during pregnancy; semaglutide must be discontinued at least 2 months prior to a planned pregnancy.
In the STEP 1 clinical trial, adverse reactions occurring in $\ge 5\%$ of patients included: nausea (44.2% vs 16.6% placebo), diarrhea (31.5% vs 15.9%), vomiting (24.8% vs 6.3%), constipation (23.4% vs 9.5%), abdominal pain (20.3% vs 10.2%), headache (14.5% vs 10.1%), and fatigue (11.0% vs 5.3%). Gastrointestinal events were predominantly mild-to-moderate and diminished as treatment continued.
Wegovy vs. Compounded Semaglutide: Clinical Comparison
| Factor | Wegovy® (Brand) | Compounded Semaglutide |
|---|---|---|
| Active Molecule | Semaglutide base (Novo Nordisk) | Semaglutide base (503A / 503B cGMP) |
| FDA Status | FDA-approved (NDA 215256) | Compounded under FD&C Act Section 503A |
| Device | Single-dose autoinjector pen | Multi-dose vial + insulin syringes |
| Dose Strengths | 0.25mg up to 2.4mg | Custom calibrated titration doses |
| Starting Price | $899/mo (Save $100 on 1st mo) | From $99 first month promo |
| Cardiovascular Claim | FDA-approved for CV risk reduction | Not FDA-reviewed for specific claims |
Frequently Asked Questions
What is Wegovy and what are its FDA-approved indications?
Wegovy® (semaglutide 2.4 mg) is an FDA-approved injectable prescription medicine used with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI >= 30) or overweight (BMI >= 27) with at least one weight-related condition (e.g. hypertension, dyslipidemia, type 2 diabetes). It is also FDA-approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or stroke) in adults with cardiovascular disease and obesity or overweight.
How much does Wegovy cost through Telehealth FX?
Through Telehealth FX, authentic Wegovy is offered at a flat rate of $899 per month across all five dose strengths (0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg). First-time orders receive an introductory discount saving up to $100 auto-applied at checkout ($799 for month 1). The monthly rate includes complete physician care, titration monitoring, and free temperature-controlled 2-day delivery with zero membership fees.
How much weight do patients lose on Wegovy according to clinical trials?
In the landmark 68-week STEP-1 trial (published in NEJM, n=1,961), patients receiving semaglutide 2.4mg achieved a mean weight reduction of 14.9% of body weight (an average loss of 33.7 lbs / 15.3 kg) compared to 2.4% with placebo. Over 86% achieved at least 5% weight loss, and nearly one-third (32.0%) lost 20% or more of their total body weight.
What is the 5-step Wegovy titration schedule?
Wegovy follows a structured 16-week escalation to reach the 2.4 mg maintenance dose: Weeks 1–4 at 0.25 mg weekly, Weeks 5–8 at 0.5 mg weekly, Weeks 9–12 at 1.0 mg weekly, Weeks 13–16 at 1.7 mg weekly, and Week 17 onward at the full 2.4 mg weekly maintenance dose. This gradual schedule allows gastrointestinal accommodation and prevents severe adverse effects.
What were the findings of the SELECT cardiovascular trial for Wegovy?
In the SELECT trial (NEJM 2023, n=17,604), semaglutide 2.4 mg demonstrated a statistically significant 20% reduction in major adverse cardiovascular events (HR 0.80, 95% CI 0.72–0.90, p<0.001) over a mean follow-up of 39.8 months in patients with established cardiovascular disease and overweight/obesity without diabetes.
Can I use HSA or FSA funds to pay for Wegovy?
Yes. Wegovy is an FDA-approved clinical prescription for chronic weight management. The full monthly cost qualifies as an eligible medical expense under IRS Section 213(d) and can be paid using HSA or FSA debit cards.
Real Patient Reviews & Clinical Outcomes
"Down 38 lbs on authentic Wegovy through Telehealth FX. The flat pricing with zero dose-jump fees made this completely predictable financially. Medication arrived chilled in 48 hours."
"Clinician approval took under 24 hours. The once-weekly injection pen is effortless to use and my food noise completely vanished by week two."
Start Your Wegovy Program Today
$899/mo flat rate across all doses. Save up to $100 on your first order. Licensed physician care. Free cold-chain delivery.
Claim $100 Off First Order